Interestingly, we compared the sensitivity to Wee1 inhibition in a TP53 wild-type HNSCC cell line and after TP53 CRISPR/Cas9 knockout, and no difference in vulnerability was observed suggesting a somewhat more complex interaction with mutated TP5315. Here, TP53 is linked to head and neck squamous cell carcinoma.